Immatics (IMTX) Interest & Investment Income (2019 - 2026)
Immatics (IMTX) posted Interest & Investment Income of $4.5 million for Q4 2025, down 10.22% sequentially from $5.0 million in Q3 2025, and down 83.51% YoY from $27.0 million in Q4 2024.
Analysis
Immatics (IMTX) Interest & Investment Income (2019 - 2026) Analysis & Trends
Immatics has reported Interest & Investment Income for 4 years, with the latest figure at $4.5 million in Q4 2025.
- Quarterly Interest & Investment Income fell 83.51% year-over-year to $4.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.0 million (down 62.65% YoY) and the FY2025 annual result came in at $20.9 million, down 56.09% from the prior year.
- Interest & Investment Income fell to $4.5 million in Q4 2025 per IMTX's latest filing, from $5.0 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $27.0 million in Q4 2024 and troughed at -$7.3 million in Q4 2022.
- A 4-year average of $6.5 million and a median of $5.7 million in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2024 and 2025: Interest & Investment Income surged 4557.13% in 2024, then slumped 83.51% in 2025.
- Over 4 years, Interest & Investment Income stood at -$7.3 million in 2022, then surged by 91.74% to -$606830.1 in 2023, then surged by 4557.13% to $27.0 million in 2024, then plunged by 83.51% to $4.5 million in 2025.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $4.5 million, $5.0 million, and $5.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | 5.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.58 Mn |
| Mar 31, 2026 | 10.24 Mn |
| Dec 31, 2025 | 4.46 Mn |
| Sep 30, 2025 | 4.97 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | 6.59 Mn |
| Dec 31, 2024 | 27.05 Mn |
| Sep 30, 2024 | 6.47 Mn |
| Jun 30, 2024 | 10.41 Mn |
| Mar 31, 2024 | 12.36 Mn |
| Dec 31, 2023 | -606,830.11 |
| Sep 30, 2023 | 10.61 Mn |
| Jun 30, 2023 | 4.31 Mn |
| Mar 31, 2023 | 3.00 Mn |
| Dec 31, 2022 | 399.13 Mn |
| Sep 30, 2022 | 7.90 Mn |
| Jun 30, 2022 | 7.49 Mn |
| Mar 31, 2022 | 1.97 Mn |
| Dec 31, 2021 | 1.37 Mn |
| Sep 30, 2021 | 1.68 Mn |